Novo secures €1.17bn long-acting injectable deal with Nanexa

2026-09-28T09:00:00

blue-medical-injector-pens

Source:

Licensing agreement focuses on a delivery technology that provides sustained-release injectable peptides and offers potential to reduce treatment burden in obesity and type 2 diabetes.

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member